Business Wire

Trend Micro Finds 72% of Remote Workers Have Gained Cybersecurity Awareness During Lockdown

1.7.2020 13:00:00 EEST | Business Wire | Press release

Share

Trend Micro Incorporated (TYO: 4704; TSE: 4704), a global leader in cybersecurity solutions, today released survey results that show how remote workers address cybersecurity. Nearly three quarters (72%) of remote workers say they are more conscious of their organisation’s cybersecurity policies since lockdown began, but many are breaking the rules anyway due to limited understanding or resource constraints.

Trend Micro’s Head in the Clouds study is distilled from interviews with 13,200 remote workers across 27 countries on their attitudes towards corporate cybersecurity and IT policies. It reveals that there has never been a better time for companies to take advantage of heightened employee cybersecurity awareness. The survey reveals that the approach businesses take to training is critical to ensure secure practices are being followed.

The results indicate a high level of security awareness, with 85% of respondents claiming they take instructions from their IT team seriously, and 81% agree that cybersecurity within their organisation is partly their responsibility. Additionally, 64% acknowledge that using non-work applications on a corporate device is a security risk.

However, just because most people understand the risks does not mean they stick to the rules.

For example:

  • 56% of employees admit to using a non-work application on a corporate device, and 66% of them have actually uploaded corporate data to that application.
  • 80% of respondents confess to using their work laptop for personal browsing, and only 36% of them fully restrict the sites they visit.
  • 39% of respondents say they often or always access corporate data from a personal device – almost certainly breaking corporate security policy.
  • 8% of respondents admit to watching / accessing porn on their work laptop, and 7% access the dark web.

Productivity still wins out over protection for many users. A third of respondents (34%) agree that they do not give much thought to whether the apps they use are sanctioned by IT or not, as they just want the job done. Additionally, 29% think they can get away with using a non-work application, as the solutions provided by their company are ‘nonsense.’

Dr Linda K. Kaye, Cyberpsychology Academic at Edge Hill University explains: “There are a great number of individual differences across the workforce. This can include individual employee’s values, accountability within their organisation, as well as aspects of their personality, all of which are important factors which drive people’s behaviours. To develop more effective cybersecurity training and practices, more attention should be paid to these factors. This, in turn, can help organisations adopt more tailored or bespoke cybersecurity training with their employees, which may be more effective.”

“In today’s interconnected world, unashamedly ignoring cybersecurity guidance is no longer a viable option for employees,” said Bharat Mistry, Principal Security Strategist, Trend Micro. “It’s encouraging to see that so many take the advice from their corporate IT team seriously. Having said that, there are individuals who are either blissfully ignorant or worse still who think cybersecurity is not applicable them and will regularly flouter the rules. Hence having a one size fits all security awareness programme is a non-starter as diligent employees often end up being penalised. A tailored training programme designed to cater for employees may be more effective.”

The Head in the Clouds study looks into the psychology of people’s behaviour in terms of cybersecurity, including their attitudes towards risk. It presents several common information security “personas” with the aim of helping organisations tailor their cybersecurity strategy in the right way for the right employee.

About Trend Micro
Trend Micro Incorporated, a global leader in cybersecurity solutions, helps to make the world safe for exchanging digital information. Our innovative solutions for consumers, businesses, and governments provide layered security for data centers, cloud environments, networks, and endpoints. All our products work together to seamlessly share threat intelligence and provide a connected threat defense with centralized visibility and control, enabling better, faster protection. With more than 6,000 employees in over 50 countries and the world’s most advanced global threat intelligence, Trend Micro secures your connected world. For more information, visit www.trendmicro.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Funda Cizgenakad
media_relations@trendmicro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye